Evotec (XTRA:EVT) - Share price, News & Analysis

EVT fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	4/6
Financial Health	5/6
Dividends	0/6

EVT Stock Overview

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.

Rewards

Trading at 12.9% below our estimate of its fair value

Earnings are forecast to grow 42.61% per year

Earnings grew by 113.7% over the past year

Risk Analysis

Volatile share price over the past 3 months

Large one-off items impacting financial results

Shareholders have been diluted in the past year

Evotec Competitors

Vertex Pharmaceuticals

NasdaqGS:VRTX

US$68.6b

Samsung BiologicsLtd

KOSE:A207940

₩58.3t

Takeda Pharmaceutical

TSE:4502

JP¥5.9t

Lonza Group

SWX:LONN

CHF41.2b

Price History & Performance

Summary of all time highs, changes and price drops for Evotec
Historical stock prices
Current Share Price	€24.97
52 Week High	€45.83
52 Week Low	€20.16
Beta	0.98
1 Month Change	-2.61%
3 Month Change	-0.08%
1 Year Change	-32.22%
3 Year Change	6.21%
5 Year Change	99.36%
Change since IPO	58.54%

Recent News & Updates

May 16

Is Now The Time To Look At Buying Evotec SE (ETR:EVT)?

While Evotec SE ( ETR:EVT ) might not be the most widely known stock at the moment, it saw a double-digit share price...

Apr 28

Is Evotec (ETR:EVT) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

	EVT	DE Life Sciences	DE Market
7D	0.4%	1.1%	-0.4%
1Y	-32.2%	-12.3%	-12.4%

Return vs Industry: EVT underperformed the German Life Sciences industry which returned -11.6% over the past year.

Return vs Market: EVT underperformed the German Market which returned -12.9% over the past year.

Price Volatility

Is EVT's price volatile compared to industry and market?
EVT volatility
EVT Average Weekly Movement	8.9%
Life Sciences Industry Average Movement	7.8%
Market Average Movement	6.3%
10% most volatile stocks in DE Market	10.6%
10% least volatile stocks in DE Market	3.4%

Stable Share Price: EVT is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: EVT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1993	4,354	Werner Lanthaler	https://www.evotec.com

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women’s health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals.

Evotec Fundamentals Summary

How do Evotec's earnings and revenue compare to its market cap?
EVT fundamental statistics
Market Cap	€4.41b
Earnings (TTM)	€89.57m
Revenue (TTM)	€649.62m

49.3x

P/E Ratio

6.8x

P/S Ratio

Is EVT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
EVT income statement (TTM)
Revenue	€649.62m
Cost of Revenue	€496.46m
Gross Profit	€153.16m
Other Expenses	€63.59m
Earnings	€89.57m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 11, 2022

Earnings per share (EPS)	0.51
Gross Margin	23.58%
Net Profit Margin	13.79%
Debt/Equity Ratio	27.7%

How did EVT perform over the long term?

See historical performance and comparison

Valuation

Is Evotec undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

12.9%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: EVT (€24.97) is trading below our estimate of fair value (€28.65)

Significantly Below Fair Value: EVT is trading below fair value, but not by a significant amount.

Price To Earnings Ratio

PE vs Industry: EVT is poor value based on its PE Ratio (49.3x) compared to the European Life Sciences industry average (46.4x).

PE vs Market: EVT is poor value based on its PE Ratio (49.3x) compared to the German market (17.2x).

Price to Earnings Growth Ratio

PEG Ratio: EVT is poor value based on its PEG Ratio (1.2x)

Price to Book Ratio

PB vs Industry: EVT's PB Ratio (3.4x) is in line with the XE Life Sciences industry average.

Future Growth

How is Evotec forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

42.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EVT's forecast earnings growth (42.6% per year) is above the savings rate (-0.05%).

Earnings vs Market: EVT's earnings (42.6% per year) are forecast to grow faster than the German market (7.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: EVT's revenue (15.5% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: EVT's revenue (15.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: EVT's Return on Equity is forecast to be low in 3 years time (4.5%).

Past Performance

How has Evotec performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

31.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: EVT has a large one-off loss of €73.7M impacting its March 31 2022 financial results.

Growing Profit Margin: EVT's current net profit margins (13.8%) are higher than last year (8.1%).

Past Earnings Growth Analysis

Earnings Trend: EVT's earnings have grown significantly by 31.8% per year over the past 5 years.

Accelerating Growth: EVT's earnings growth over the past year (113.7%) exceeds its 5-year average (31.8% per year).

Earnings vs Industry: EVT earnings growth over the past year (113.7%) exceeded the Life Sciences industry 50.8%.

Return on Equity

High ROE: EVT's Return on Equity (6.8%) is considered low.

Financial Health

How is Evotec's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: EVT's short term assets (€1.1B) exceed its short term liabilities (€339.6M).

Long Term Liabilities: EVT's short term assets (€1.1B) exceed its long term liabilities (€535.5M).

Debt to Equity History and Analysis

Debt Level: EVT has more cash than its total debt.

Reducing Debt: EVT's debt to equity ratio has increased from 2.6% to 27.7% over the past 5 years.

Debt Coverage: EVT's debt is well covered by operating cash flow (50.6%).

Interest Coverage: EVT earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Dividend

What is Evotec current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate EVT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EVT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EVT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EVT's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as EVT has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.9yrs

Average management tenure

CEO

Werner Lanthaler (53 yo)

13.17yrs

Tenure

€4,614,000

Compensation

Dr. Werner Lanthaler, MBA, has been the Chief Executive Officer of Evotec SE (formerly known as Evotec AG) since March 2009 and serves as its Chairman of Management Board. Dr. Lanthaler has an outstanding...

CEO Compensation Analysis

Compensation vs Market: Werner's total compensation ($USD4.93M) is above average for companies of similar size in the German market ($USD2.37M).

Compensation vs Earnings: Werner's compensation has increased by more than 20% in the past year.

Leadership Team

Experienced Management: EVT's management team is seasoned and experienced (5.9 years average tenure).

Board Members

Experienced Board: EVT's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/23 00:00
End of Day Share Price	2022/05/23 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31